![Hans G. Nilsson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hans G.
Nilsson is currently the Director at PharmNovo AB since 2018.
Prior to this, he was the President at AstraZeneca R&D Boston, Inc.
| Unternehmen | Position | Beginn |
|---|---|---|
PharmNovo AB
 PharmNovo AB Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company | Direktor/Vorstandsmitglied | 01.01.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
AstraZeneca R&D Boston, Inc.
 AstraZeneca R&D Boston, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets prescription pharmaceutical drugs | Präsident | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 2 |
|---|---|
AstraZeneca R&D Boston, Inc.
AstraZeneca R&D Boston, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets prescription pharmaceutical drugs | Health Technology |
PharmNovo AB
PharmNovo AB Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
